Innovative cement that delivers anti-cancer drugs for patients with bone metastasis
Next generation anti-cancer drugdelivering cement for bone metastasis patients
This study is testing a new kind of bone cement that can deliver cancer-fighting drugs right where they’re needed in the bones, helping to ease pain and improve life for people dealing with cancer that has spread to their bones.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Curer INC NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-11141270 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of bone cement that can deliver anti-cancer drugs directly to areas affected by bone metastasis. The cement is designed to be injected into the bone in a minimally invasive way, targeting the degeneration caused by cancer cells. By combining drug delivery with bone regeneration, the goal is to not only reduce cancer progression but also alleviate pain and improve the quality of life for patients suffering from bone metastasis. This approach aims to address the limitations of current treatments that do not promote bone healing.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with bone metastasis who are experiencing pain and bone degeneration due to cancer.
Not a fit: Patients with bone metastasis who are not experiencing significant pain or degeneration may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve pain management and bone health for patients with bone metastasis, potentially extending their quality of life.
How similar studies have performed: While the approach of using drug-delivering bone cement is innovative, similar strategies in cancer treatment have shown promise, indicating potential for success.
Where this research is happening
Cambridge, United States
- Curer INC — Cambridge, United States (Active)
Researchers
- Principal investigator: Jang, Hae Lin — Curer INC
- Study coordinator: Jang, Hae Lin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.